Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers

Next Previous
X
Search
Trial Profile

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications CNS cancer; Ependymoma; Germ cell and embryonal neoplasms; Glioma; Gliosarcoma; Medulloblastoma; Meningioma; Papilloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Jan 2023 Planned End Date changed from 21 May 2024 to 21 Apr 2027.
    • 13 Jan 2023 Planned primary completion date changed from 22 May 2023 to 21 Apr 2026.
    • 17 Feb 2022 Planned primary completion date changed from 31 May 2023 to 22 May 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top